By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this ...

Wegovy: sales of weight loss injection more than double - The company said more than 45 million people were now ‘benefitting ...

Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

The entertainment company topped Wall Street expectations on core metrics; meanwhile, its streaming push continues. Shares in Nissan fell while Honda stock closed higher, reflecting investor views ...